Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice

Biological Chemistry

Volumn 388, Issue 2, 2007, Pages 221-226

  Parker, Jeremy C ^a   Irwin, Nigel ^a   Lavery, Kerry S ^a   Green, Brian D ^a   O'Harte, Finbarr P M ^a   Gault, Victor A ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

(Pro3)GIP; Antagonism; Exendin(9 39)amide; Glucose homeostasis; Insulin secretion; ob ob mice

Indexed keywords

AMIDE; EXENDIN[9-39]AMIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HORMONE RECEPTOR; INCRETIN; INSULIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC OBESITY; FEEDING; GLUCOSE BLOOD LEVEL; METABOLIC PARAMETERS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC INHIBITORY POLYPEPTIDE; INJECTIONS, INTRAPERITONEAL; INSULIN; MICE; MICE, OBESE; OBESITY; PEPTIDE FRAGMENTS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

MUS;

EID: 33846637891     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2007.024     Document Type: Article

References (25)

1. Bailey, C.J., Flatt, P.R., and Atkins, T.W. (1982). Influence of the genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 6, 11-21.
2. Burington, R.S. (1973). Handbook of Mathematical Tables and Formulae (New York, USA: McGraw-Hill).
3. Creutzfeldt, W. (2001). The entero-insular axis in type 2 diabetesincretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109, S288-S303.
4. Eng, J., Kleinmann, W.A., Singh, L., Singh, G., and Raufman. J.P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402-7405.
5. Flatt, P.R. and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/q) mice. Diabetologia 20, 573-577.
6. Gault, V.A., O'Harte, F.P.M., Harriott, P., and Flatt, P.R. (2002). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290, 1420-1426.
7. 3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and post-prandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46, 222-230.
8. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54, 2436-2446.
9. Goke, R., Fehmann, H.C., Linn, T., Schmidt, H., Krause, M., Eng, J., and Goke, B. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36) amide receptor of insulin secreting β-cells. J. Biol. Chem. 268, 19650-19655.
10. Green, B.D., Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2004). Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. 10, 3651-3662.
11. Green, B.D., Irwin, N., Gault, V.A., Bailey, C.J., O'Harte, F.P., and Flatt, P.R. (2005). Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J. Endocrinol. 185, 307-317.
12. Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F., and Drucker, D.J. (2004). Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPPIV inhibitors. Diabetes 53, 1326-1335.
13. Holst, J.J. and Deacon, C.F. (2004). Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 4, 589-596.
14. Irwin, N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P., and Flatt, P.R. (2004). Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol. Chem. 385, 845-852.
15. Kolligs, F., Fehmann, H.C., Goke, R., and Goke, B. (1995). Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin(9-39) amide. Diabetes 44, 16-19.
16. Kolterman, O., Buse, J., Fineman, M., Gaines, E., Heintz, S., Bicsak, T., Taylor, K., Kim, D., Aiisporna, M., Wang, Y., and Baron, A. (2003). Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 3082-3089.
17. Light, P.E., Manning Fox J.E., Riedel, M.J., and Wheeler, M.B. (2002). Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol. Endocrinol. 16, 2135-2144.
18. Meier, J.J., Nauck, M.A., Schmidt, W.E., and Gallwitz, B. (2002). Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 107, 1-13.
19. Meier, J.J., Gallwitz, B., and Nauck, M.A. (2003). Glucagon-like peptide 1 and gastric inhibitory polypeptide; potential applications in type 2 diabetes mellitus. Pept. Ther. 17, 93-102.
20. Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoti, S., Kajikawa, M., Kuroe, A., et al. (1999). Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 14843-14847.
21. -/- mice. Diabetes 47, 1046-1052.
22. Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansoita, T., Drucker, D.J., Wollheim, C., Burcelin, R., and Thorens, B. (2004). Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest. 113, 635-645.
23. Schick, R.R., Zimmermann, J.P., vorm Walde, T., and Schusdziarra, V. (2003). Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1427-R1435.
24. Stevens, J.F. (1971). Determination of glucose by an automatic analyser. Clin. Chem. Acta 32, 199-201.
25. Thorens, B., Porret, A., Buhler, L., Deng, S.P., Morel, P., and Widmann. C. (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin(9-39) an antagonist of the receptor. Diabetes 42, 1678-1682.